Begins clinical trials of an AIDS vaccine based on a recombinant form of the gp 120 envelope protein as a potential treatment for HIV infection. According to Genentech, the study "is being conducted to determine if post-exposure immunization with recombinant gp 120 can significantly boost the immune system of persons infected with HIV." The trial is being conducted at Walter Reed Army Institute of Research in Washington, D.C., and will involve 55 patients studied over a 10-month period. Genentech also reports the company "is currently evaluating the possibility of a separate human pilot study to test recombinant gp 120 as a potential vaccine to protect uninfected individuals against HIV infection".
You may also be interested in...
With the meetings available on television, access can be assured for just about everyone, and the US FDA can avoid another gut punch to its credibility.
Japan approves a batch of new products and indications, including Daiichi Sankyo's Enhertu in a high-need indication after a rapid review and Takeda's Zejula, which will be made available to selected patients before its reimbursement listing.
Public Company Edition: Outside the US, Zai Lab raised more in its recent Hong Kong initial public offering – $766.4m – than PMV, Prelude, Taysha, Graybug and Greenwich combined. Also, Gilead priced debt to fund its $21bn Immunomedics buy and ADC Therapeutics raised $204m.